Drug interactions
Aprepitant + Infigratinib
Severity: Major
Aprepitant and Infigratinib: major interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Aprepitant may increase infigratinib exposure through CYP3A4 inhibition. This could worsen hyperphosphatemia-related effects, ocular toxicity and other adverse reactions.
What this interaction means in plain words
Aprepitant and Infigratinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for.
Why it happens
Aprepitant inhibits CYP3A4, the main metabolic pathway of infigratinib.
What to do
Avoid moderate CYP3A inhibitors and select an alternative antiemetic. If unavoidable, monitor for infigratinib toxicity including phosphate levels and vision.
What to ask your pharmacist
- Does the benefit of taking both outweigh the risk in my case?
- Do I need any blood test, ECG or other check while on both?
- What early warning signs should I watch for, and what should I do if they appear?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Aprepitant and Infigratinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Aprepitant
- Aprepitant + Lomitapide Contraindicated
- Aprepitant + Pimozide Contraindicated
- Aprepitant + Avapritinib Major
- Aprepitant + Bosutinib Major
- Aprepitant + Carbamazepine Major
- Aprepitant + Cobicistat Major
Frequently asked questions
Can I take Aprepitant with Infigratinib?
MediHelp rates the interaction as major. Aprepitant and Infigratinib can interact in a way that may be serious. Using them together is sometimes necessary, but it needs a deliberate decision by the prescriber, a plan for monitoring, and clear advice on the warning signs to watch for. Aprepitant may increase infigratinib exposure through CYP3A4 inhibition. This could worsen hyperphosphatemia-related effects, ocular toxicity and other adverse reactions.
How serious is the interaction between Aprepitant and Infigratinib?
MediHelp rates it major, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid moderate CYP3A inhibitors and select an alternative antiemetic. If unavoidable, monitor for infigratinib toxicity including phosphate levels and vision.
What other medicines interact with Aprepitant?
MediHelp also lists interactions of Aprepitant with, for example, Lomitapide, Pimozide, Avapritinib. The full list is on the Aprepitant page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
